Coeptis Therapeutics Holdings, Inc. announced that it has expanded its exclusive license agreement with the University of Pittsburgh to include the SNAP-CAR technology platform in natural killer (NK) cells. This amended agreement builds upon the original exclusive license agreement with theUniversity of Pittsburgh for SNAP-CAR T-Cell, a " universal" CAR T technology platform designed to target multiple antigens simultaneously and potentially address a range of he hematologic and solid tumors, including HER2-expressing cancer. The addition of SNAP-CAR NK adds a third NK-focused technology to Coeptis' development portfolio.

Recently Coeptis completed an exclusive license agreement with Deverra Therapeutics, which included rights to a proprietary allogeneic stem cell expansion and differentiation platform for the generation of NK cells from pooled donor cord blood CD34+ cells that are being used without HLA matching in first-in-human clinical trials. This highly scalable and cost-effective cell generation platform combined with the universal SNAP-CAR technology has the potential to generate a first-in-class fully universal (no HLA matching and antigen agnostic) targeted cell therapy. Coeptis has also obtained exclusive rights from VyGen Bio to negotiate towards the acquisition of the GEAR cell therapy and companion diagnostic platforms, including CD38-GEAR-NK, a natural killer (NK) cell therapy for the treatment of CD38+ cancers with an initial focus on multiple myeloma.